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Abstract  
Background: Sleep disorders are frequent symptoms described in psychiatric patients with major 
depression or schizophrenia. These patients also exhibit changes in the sleep architecture 
measured by polysomnography (PSG) during sleep. The aim of the present study was to identify 
potential biomarkers that would facilitate the diagnosis based on polysomnography (PSG) 
measurements. 
Subjects and Methods: 30 patients with schizophrenia, 30 patients with major depression and 30 
healthy control subjects were investigated in the present study. The mean age in the group with 
schizophrenia was 36.73 (SD 6.43), in the group of patients with depression 40.77 (SD 7.66), in the 
healthy controls group 34.40 (SD 5.70). The gender distribution was as follows: 18 male, 12 female 
in the group with schizophrenia; in the group of patients with depression 11 male, 19 female; in the 
control group 16 male and 14 female. All subjects underwent polysomnography (PSG) for a 
minimum time of 8 hours according to the criteria of Rechtschaffen & Kales (1968). The following 
polysomnographic (PSG) parameters were analyzed: sleep latency (SL), total sleep time (TST), 
waking time after sleep onset (WTASO), number of awakenings (NAW), slow wave sleep (SWS), 
rapid eye movement sleep (REM), rapid eye movement sleep latency (REML), first REM period 
(REM 1), and first NREM period (NREM 1). We tested the potential of multiple sleep variables to 
predict diagnosis in different groups by using linear discriminate analysis (LDA). 
Results: There were significant differences in polysomnography (PSG) variables between healthy 
control subjects and psychiatric patients (total sleep time, sleep latency, number of awakenings, 
time of awakening after sleep onset, REM 1 latency, REM 1 and index of endogenous periodicity). 
Importantly, LDA was able to predict the correct diagnosis in 88% of all cases. 
Conclusions: The presented analysis showed commonalities and differences in polysomnography 
(PSG) changes in patients with major depressive disorder and in patients with schizophrenia. Our 
results underline the potential of polysomnography (PSG) measurements to facilitate diagnostic 
processes.  
 
 
 
 
Introduction 
 Schizophrenia and the major depressive 
disorder (MDD) are both among the most frequent 
psychiatric disorders and make up a substantial share in 
the global burden of disease [1, 2]. A reliable diagnosis 
is crucial in providing efficient treatment strategies for 
patients. However, until today diagnostic processes 
have largely relied on clinical evaluation and reliable 
biomarkers have not yet been identified. It has been 
suggested that there is a substantial overlap in the 
clinical symptomatology in patients with MDD and 
patients with schizophrenia. Specifically, sleep 
disturbances represent a common symptom that can be 
found in all stages of MDD and schizophrenia [3, 4]. In 
some cases this can lead to low reliability of established 
diagnostic procedures. Therefore, EEG measurements 
could provide an important tool to detect biomarkers [5] 
in order to investigate the sleep architecture before the 
treatment and over the course of the disease.  
Polysomnography or sleep EEG provides 
numerous variables to objectify sleep characteristics by 
means of EEG recordings while subjects are asleep. 
Among those, the most frequently used variables are: 
the amount of slow-wave sleep, sleep latency, total 
sleep time, total awake time, REM sleep latency and the 
percentage of REM sleep. It has been suggested [6] 
that the index of endogenous perturbation of sleep 
(IEP) might be an important parameter to characterize 
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sleep architecture in psychiatric patients. The IEP 
represents the ratio between REM1/NREM1 (IEP = 
REM1/NREM1). It has been reported that the IEP is a 
significant marker in patients with major depression 
[6]. 
 Numerous abnormalities have been reported in 
schizophrenia, as measured by polysomnography 
(PSG) and particularly during rapid-eye-movement 
(REM) phases. Significant changes in sleep latency, 
total sleep time and sleep efficiency index have been 
reported in patients with schizophrenia as compared to 
healthy controls in a recent meta-analysis of sleep 
variables [7]. Additionally, some studies have reported 
changes in the total awake time [8-10], slow-wave 
sleep [11] and rapid-eye-movement latency (REML) 
[8, 12]. Moreover, the REM percentage of total sleep 
time [7, 13] seems to be abnormal in those patients, but 
not all studies confirmed these findings [12-19]. It has 
also been reported that the severity of clinical symptoms 
is related to EEG disturbances during sleep [13, 20, 21]. 
 Similarly to patients with schizophrenia, 
subjects with depression show abnormal sleep 
architecture – especially during REM sleep periods [5]. 
A recent meta-analysis of abnormal EEG patterns in 
patients with MDD suggests that abnormal REM density 
and NREM sleep might represent potential biomarkers 
that persist beyond remission [22]. These abnormalities 
have been related to the severity of clinical symptoms 
[22]. Finally, it has also been suggested that abnormal 
sleep architecture might represent a vulnerability factor 
for affective disorders [23-25]. 
In the present study sleep disturbances in 
patients with schizophrenia, depression as well as in 
healthy controls were investigated with 
polysomnographic measurements. The aim was to 
identify reliable biomarkers associated with MDD and 
schizophrenia. The sleep variables were entered into 
a multivariate classification model to allow prediction 
of diagnostic categories. In this way the usability of 
polysomnographic measurements in clinical 
diagnostic procedures was investigated. 
Our hypotheses were that: 1) the structure 
and architecture of nocturnal sleep as measured with 
polysomnography (PSG) in schizophrenic and 
depressive patients and in healthy control subjects 
show significant group differences with regard to 
some parameters (variables) of the polysomnogram; 
and 2) the variables of nocturnal sleep in 
polysomnogram have a good potential to help the 
differential diagnostic process in schizophrenia and 
major depressive disorders. 
 
Subjects and Methods 
We tested 30 patients with MDD (age, 
gender), 30 patients with schizophrenia (age, gender) 
and 30 healthy controls (age, gender). All patients 
were diagnosed by an experienced clinical psychiatrist 
and fulfilled ICD-10 criteria (World Health 
Organization, n.d.) [27] for either major depression 
(F32.2) or schizophrenia (F20). The mean duration of 
the illness in the group with schizophrenia was 12.60 
years (SD 6.53) and in the group with depression 
12.93 years (SD 6.13). All patients were in-patients. 
The exclusion criteria for all subjects were the 
following: presence of neurological or medical illness, 
current or recent alcohol abuse or drug addiction 
(except for nicotine), presence of any psychiatric 
disorder in the group of healthy control subjects and 
any comorbid psychiatric disorder in patients. All 
subjects provided written informed consent to 
participate in the study. The study was approved by 
the Ethics Committee of the University of Belgrade.  
All subjects underwent a 16-channel EEG 
recording for 24 hours using the Oxford Medilog 9000 
ambulatory EEG system plus 2 EOG 
(electrooculogram) and 1 EMG (submental 
electromyography) channels. The analysis was 
restricted to an 8-hour-period from 10 p.m. until 6 a.m. 
For the subsequent statistical analysis the following 
sleep parameters were extracted: total sleep time, 
sleep latency, number of awakenings, time of 
awakening after sleep onset, slow wave sleep, REM 
latency, REM 1, Non-REM 1, index of endogenous 
periodicity (Table 1). 
Table 1: Sleep variables. 
Sleep variable Acronym Definition 
Sleep latencyL SL From the moment the lights 
are turned off to consecutive 
10 minutes of stage 2, 3 or 4 
(minutes) 
Total sleep time TST Minutes of sleep during the 
recording of sleep 
Waking Time after Sleep Onset  WTASO or 
TAT 
Waking Time after Sleep 
Onset (minutes) 
Number of Awakenings  NAWs Number of Awakenings 
through the night 
Slow-wave-sleep  SWS Duration of SWS time in TST 
(minutes) 
Rapid-eye-movement sleep  REM Duration of REM time in TST 
(minutes) 
Rapid-eye-movement sleep latency REML REML Minutes from sleep onset to 
the first REM sleep 
First REM period  REM 1 First REM period (minutes) 
First NREM period  NREM 1 First NREM period (minutes) 
Index of Endogenous Periodicity  IEP Ratio between REM 1 and 
NREM 1 
 
Clinical Scales 
For the assessment of clinical symptoms 
during the study and for the sample definition two 
psychiatric instruments were used: Positive and 
Negative Schizophrenia Scale (PANSS) for the 
differentiation of positive and negative subtypes of 
schizophrenia and the Hamilton Depression Scale 
(HAMD) for the measurement of depressive 
symptoms.  
 
Statistical Analysis 
All statistical analyses were conducted using 
the R statistical language of computing [26] (Team et 
al. 2010). Initially, an analysis-of-variance (ANOVA) 
was conducted with the sleep variables as dependent 
variables to indentify differences between the 
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diagnostic groups (healthy, schizophrenia, MDD). In 
case of significant main effects, post-hoc tests were 
conducted to specify group differences. In order to 
investigate the relationship between sleep 
polysomnographic parameters and clinical 
symptomatology a linear regression analysis was 
conducted with the sleep parameters as dependent 
variable. In the group of schizophrenic patients, 
PANSS positive and PANSS negative scores were 
used as predictor variables whereas HAMD scores 
were used as predictor variables in the MDD group. 
The relationship between age and parameters of 
polysomnogram was investigated using a linear 
regression with age as a predictor for parameters of 
polysomnogram, separately for every diagnostic group 
(schizophrenia, MDD, healthy controls). 
 
Results 
ANOVA indicated significant main effects of 
the factor group (schizophrenia, MDD, healthy 
controls) for the total sleep time, sleep latency, 
number of awakenings, the time of awakening after 
sleep onset, REM 1 latency, REM 1 and index of 
endogenous periodicity. In order to investigate those 
results in a more detailed way a post-hoc analysis 
was conducted (Table 2).  
Table 2: ANOVA results with main effects of diagnosis 
(healthy, schizophrenia, depression) for different sleep 
parameters. 
Sleep Variables F-value p-value 
Total Sleep Time 78.455 0.0063 
Sleep Latency 217.759 <0.0001 
Number of Awakenings 334.386 <0.0001 
Waking Time after Sleep Onset 768.521 <0.0001 
Slow wave Sleep 18.292 0.1797 
REM 1 Latency 58.972 0.0172 
REM 33.024 0.0726 
REM 1 189.857 <0.0001 
Non-REM 1 17.977 0.1834 
Index of endogenous Periodicity 51.884 0.0252 
 
This analysis indicated significant differences 
between schizophrenic patients and healthy controls 
for the following sleep variables: total sleep time, 
sleep latency, number of awakenings, time of 
awakening after sleep onset, REM 1 latency, REM 1, 
index of endogenous periodicity. The group of 
subjects with MDD differed from the healthy control 
group regarding the following sleep variables:    sleep  
Table 3: Post-hoc t-test investigating sleep variable differences 
between diagnostic groups. 
  
Schizophrenia vs 
Controls 
Depression vs Controls 
Schizophrenia vs 
Depression 
Sleep Variables t df p t df p t df p 
Total Sleep Time -3,148 57,23 0,003 1,727 55,91 0,090 -4,503 57,64 <0,001 
Sleep Latency 4,150 37,16 <0,001 7,370 57,92 <0,001 0,387 37,73 0,701 
Number of 
Awakenings 
5,851 55,78 <0,001 6,725 57,80 <0,001 0,000 54,48 1,000 
Waking Time 
after Sleep Onset 
10,059 36,26 <0,001 9,793 38,34 <0,001 1,058 57,03 0,294 
Slow wave Sleep 1,732 55,14 0,089 -8,204 55,06 <0,001 8,902 48,75 <0,001 
REM 1 Latency -2,861 54,35 0,006 2,222 51,60 0,031 -4,423 57,39 <0,001 
REM -1,772 57,79 0,082 0,727 57,45 0,470 -2,553 56,61 0,013 
REM 1 -4,511 53,36 <0,001 0,554 57,12 0,582 -4,776 56,22 <0,001 
Non-REM 1 1,718 55,19 0,092 -8,204 55,06 <0,001 8,898 48,81 <0,001 
Index of 
endogenous 
Periodicity 
-4,385 54,52 <0,001 6,903 42,58 <0,001 -9,485 49,59 <0,001 
 
latency, number of awakenings, the time of awakening 
after sleep onset, slow wave sleep, REM 1 latency, 
Non-REM 1 and index of endogenous periodicity. 
Schizophrenic patients differed from MDD patients 
with respect to the total sleep time, slow wave sleep, 
REM 1 latency, REM, REM 1, Non-REM 1 and index 
of endogenous periodicity. 
Table 4: Regression analysis with PANSS positive and 
negative scores predicting different sleep variables in 
schizophrenic subjects. 
  PANSS Positive PANSS Negative 
Sleep variables B t p b t p 
Total Sleep Time 0,178 0,272 0,787 0,814 0,949 0,351 
Sleep Latency 0,200 0,454 0,653 -0,318 -0,542 0,592 
Number of Awakenings -0,348 -0,547 0,589 -0,143 -0,167 0,868 
Waking Time after Sleep 
Onset 
-0,591 -0,862 0,396 -0,837 -0,918 0,366 
Slow wave Sleep -0,671 -0,992 0,330 -0,279 -0,305 0,763 
REM 1 Latency -0,220 -0,346 0,732 0,746 0,889 0,382 
REM 0,877 1,612 0,118 -0,153 -0,203 0,841 
REM 1 -0,035 -0,059 0,953 -0,328 -0,418 0,679 
Non-REM 1 -0,652 -0,962 0,344 -0,280 -0,305 0,762 
Index of endogenous 
Periodicity 
1,213 0,467 0,644 -1,651 -0,477 0,637 
 
In subjects with major depression, especially 
REM 1 latency and REM 1 showed a significant 
relationship to clinical symptomatology measured by 
HAMD scores (see Table 5). Interestingly, none of the 
sleep variables showed a significant relationship with 
clinical symptomatology in subjects with schizo-
phrenia, measured by PANSS positive or PANSS 
negative score. This might suggest that sleep EEG 
abnormalities found in those patients represent 
general trait markers or a vulnerability factor that is 
not related to the current state of the disease (see 
Table 4). 
Table 5: Regression analysis with HAM-D scores predicting 
different sleep variables in depressed subjects. 
Sleep variables b t p 
Total Sleep Time 0,397 0,714 0,481 
Sleep Latency 1,221 1,196 0,242 
Number of Awakenings -0,217 -0,283 0,779 
Waking Time after Sleep Onset 0,385 0,526 0,603 
Slow wave Sleep 1,342 1,360 0,185 
REM 1 Latency 1,032 2,069 0,048 
REM -0,232 -0,376 0,710 
REM 1 2,166 4,217 <0.001 
Non-REM 1 1,340 1,360 0,185 
Index of endogenous Periodicity 1,049 0,676 0,505 
 
 
The linear discriminate analysis (LDA) was 
conducted to investigate the usability of sleep EEG 
parameters as a tool to assist in differential diagnosis. 
With the use of sleep EEG parameters the overall 
diagnostic accuracy predicted by LDA was 88.78% 
(see Table 6).  
Table 6: Confusion matrix showing the prediction from linear 
discriminant analysis (LDA). 
  Diagnose as detected by LDA 
True diagnose schizophrenia depression healthy control 
schizophrenia 25 1 4 
depression 2 26 2 
healthy control 0 1 29 
 
 
Sensitivity for patients with schizophrenia was 
92.31%, for patients with MDD 92.86% and for healthy 
controls 80.56 %. The specificity for patients with 
schizophrenia was 90.62%, for MDD 92.86% and for 
healthy controls 98.15%. This suggests that sleep 
EEG parameters might be sufficiently reliable to serve 
in day-to-day clinical practice. 
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Figure 1: Barplot indicating mean z-scores of different sleep 
variables for schizophrenic subjects, depressed subjects and 
healthy controls. Error-bars indicate 95%-confidence intervals. TST 
(total sleep time), SL (sleep latency), NAW (number of awakenings), 
WTASO (waking time after sleep onset), REM1lat (REM 1 latency), 
SWS (slow wave sleep), NREM 1 (Non-REM 1), IEP (index of 
endogenous periodicity). 
 
 
Discussion  
In the present study we provide evidence for 
sleep disturbances in patients with MDD and 
schizophrenia as measured by EEG during sleep. 
Several parameters showed significant alterations in 
the patients’ groups as compared to healthy controls. 
Among all sleep parameters the changes in the IEP 
index differed to the largest extent between the two 
psychiatric populations showing an increase in MDD 
patients and a decrease in patients with 
schizophrenia. Thus IEP might have the strongest 
discriminative potential to separate patients with 
schizophrenia and patients with MDD. Most 
interestingly, owing to the linear discriminate analysis, 
the correct diagnose could be detected 
(schizophrenia, depression or healthy) in 88%. Thus 
parameters derived from sleep EEG measurements 
provide biomarkers that might support the diagnostic 
process.  
However, it needs to be noted that there are 
some limitations to the presented analysis. Firstly, the 
presented results are derived from a sample of 
moderate size. Even though there is substantial 
support for the reported findings by previous studies 
[7, 9-13, 28], further investigations with larger samples 
are needed to confirm our observations. Also, there 
are some potential covariates that might have deluded 
the presented effects. Importantly, multiple studies 
report that antidepressants [29-32] or antipsychotic 
medication [33] have some effect on sleep variables 
measured by EEG. Also other environmental factors 
such as the smoking status [34], alcohol abuse [35] or 
cannabis abuse [36] might represent potential 
confounding factors for EEG measurements. 
Sleep-onset and sleep-maintenance insomnia 
are characteristic features of schizophrenic patients 
regardless of either their medication status (drug-
naive or previously treated) or the phase of the clinical 
course (acute or chronic). Regarding the sleep 
architecture, the majority of studies indicate that stage 
4 NREM sleep and REM latency are reduced in 
schizophrenia, whereas REM sleep duration tends to 
remain unchanged [9]. 
Disturbed sleep can be found in 30-80% of 
schizophrenic patients, depending on the degree of 
psychotic symptomatology. Measured by 
polysomnography, reduced sleep efficiency and total 
sleep time, as well as increased sleep latency, are 
found in most patients with schizophrenia and appear 
to be an important part of the pathophysiology of this 
disorder. Some studies also reported alterations of 
stage 2 sleep, slow-wave sleep and REM sleep 
variables, i.e. reduced REM latency and REM density 
[9]. A number of sleep parameters, such as the 
amount of slow wave sleep and the REM latency are 
significantly correlated to clinical variables, including 
severity of illness, positive symptoms, negative 
symptoms, outcome, neurocognitive impairment and 
brain structure. There are no consistent effects of first-
generation antipsychotics on measures of sleep 
continuity and sleep structure, including the 
percentage of sleep stages or sleep and REM latency 
in healthy controls. In contrast to first-generation 
antipsychotics, the atypical antipsychotics (clozapine, 
olanzapine, quetiapine, risperidone, ziprasidone and 
paliperidone) demonstrate a relatively consistent 
effect on measures of sleep continuity, with an 
increase in either total sleep time or sleep efficiency, 
and individually varying effects on other sleep 
parameters. On the other hand, withdrawal of such 
treatment is followed by a change in the sleep 
structure mainly in the opposite direction, indicating a 
deterioration of the quality of sleep. Specific sleep 
disorders, such as RLS (Restless Legs Syndrome), 
sleep-related breathing disorders, night-eating 
syndrome, somnambulism and rhythm disorders have 
been described as possible adverse effects of 
antipsychotics and should be considered in the 
differential diagnosis of disturbed or turbulent sleep in 
this population [10]. 
Delta wave deficits during sleep have also 
been observed in patients with schizophrenia. 
Decreased slow-wave sleep is reported to be 
associated with negative symptoms. Laterality of 
frontal cortex delta wave counts during all-night sleep 
was investigated by a computer analysis. Total delta 
wave counts were lower in patients with schizophrenia 
than in control subjects. Control subjects showed 
significantly higher delta wave counts in the right 
frontal cortex than in the left. This asymmetry was not 
observed in patients with schizophrenia. These 
findings suggest that reduced right frontal delta wave 
dominance is involved in the pathophysiology of 
schizophrenia [11]. 
The investigation of sleep in depression was 
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performed in a group of 60 samples divided into three 
subgroups: a) healthy, b) exogenic (reactive, non-
psychotic) and c) endogenic (psychotic) depressives. 
130 parameters (variables) of hypnograms were 
exposed to exact statistical testing. With 130 
parameters (variables) of polysomnogram (PSG) 
discriminative models were formed (Discriminative 
Profile of Sleep - DPS). The dominant discriminative 
factor in reactive non-psychotic depression was the 
increased number of nocturnal awakenings (NAW) - 
hypnofragmentic exogenic depression. The transition 
in endogenic psychotic depression was characterized 
by the following: shortening of REM-latency, reduction 
of delta-sleep and increase in the Index of Endogenic 
Periodicity/Perturbation (IEP = REM 1/ NREM 1)- 
hypnodisrrhythmic endogenic depression [6]. These 
models contribute not only to the problem of correct 
differential diagnosis, but also to the accurate choice 
of therapy depending on the course (evolution, de-
evolution) of the illness and to the appraisal of 
therapeutic sensitivity-insensitivity and affectivity of 
pharmacotherapy.  
Riemann et al., 2001 [37] has demonstrated 
in his original clinical study that in depression, besides 
disturbances of sleep continuity, polysomnograms are 
characterized by a reduction of slow wave sleep, a 
shortening of REM latency, prolongation of the first 
REM period and increased REM density. These 
results correspond mostly to the results of our 
research and support our thesis about the 
neurophysiologic and clinical importance of alterations 
of the REM/NREM ratio by psychiatric disorders. 
As a conclusion, the presented results confirm 
previous reports of substantial abnormalities in the 
sleep architecture as measured by EEG in patients 
with depression and schizophrenia. Depression and 
schizophrenia show different patterns of changes in 
sleep variables. Most importantly, the discriminate 
analysis provided a correct diagnosis in 88% 
suggesting a potential role of sleep EEG 
measurements (polysomnography) for the clinical 
diagnostic routine and for more targeted 
pharmacotherapy. Some parameters (variables) of 
polysomnograms show significant differences when 
measuring sleep in patients with schizophrenia and 
sleep in patients with depression. The Index of 
Endogenous Periodicity (IEP = REM 1/ NREM 1) 
could be a state marker for affective versus 
schizophrenia spectrum disorders. This index makes 
the sleep test very economical – the nocturnal sleep 
registration can be shortened to 1.5 hour (the first 
REM/NREM cycles).  
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